The Clinical Trials Office's (CTO) mission is to support clinical investigators in the development and implementation of clinical research studies at the Moffitt Cancer Center. The infrastructure in place assists the investigators with the following activities: ? Assisting investigators in screening and enrolling patients for clinical studies. ? Providing data management support for clinical studies. ? Assisting the Principal Investigators in the compliant conduct of clinical studies, including assisting in the submission of required regulatory documents, annual reviews and adverse event reporting. ? Providing staff training and education pertaining to clinical studies. ? Coordinating and implementing protocol related orders for study patients. ? Preparing medical and research records for audits. The CTO has seen an average combined accrual to clinical intervention, prevention intervention, and supportive care intervention trials of 2,856 subjects/year for FY's 2006-2010 (an average of 1,176 subjects/year for clinical intervention trials, 780 subjects/year for prevention intervention trials, and 872 subjects/year for supportive care intervention trials). FY 2010 was especially robust, with accruals of 1,287,2,406, and 1,001 subjects to clinical, prevention, and supportive care intervention trials, respectively. The accrual to investigator-initiated trials (external peer reviewed + institutional) for all intervention studies has remained greater than 60% for all 5 years and was 84% in FY 2010. Clearly, these accrual levels, as well as the complexity and increased data collection requirements of current trials, have necessitated growth of the CTO and demand increased efficiency. The CTO operates efficiently for the cost effective management of clinical trials at the Cancer Center. The accrual to all intervention, prevention intervention and supportive care intervention trials continues to increase on a yearly basis. The Core requests CCSG Support of $570,611, which is 13% of its operational budget.

Public Health Relevance

The centralized Clinical Trials Office provides consistent, cost-effective services by qualified research staff to support the large clinical trial portfolio generated by the Phase I program, the disease-based clinical departments (phase 11 and 111 trials), and the cancer prevention and control investigators. The core also provides standardized education and orientation to all core staff and investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA076292-14
Application #
8491592
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-06-22
Budget End
2013-01-31
Support Year
14
Fiscal Year
2012
Total Cost
$299,462
Indirect Cost
$127,203
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75
Puri, Sonam; Hyland, Kelly A; Weiss, Kristine Crowe et al. (2018) Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors. Support Care Cancer 26:2911-2918
Gonzalez, Brian D; Small, Brent J; Cases, Mallory G et al. (2018) Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia. Cancer 124:499-506
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430

Showing the most recent 10 out of 1254 publications